Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Cardiovascular disease is "unacceptably" high and increasing among American adults ages 20 to 44, requiring aggressive prevention.
Read Full NewsThe rheumatology year in review highlights FDA approvals and pivotal data readouts.
Johnson & Johnson plans to initiate a phase 3 study based off the positive data.
Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.
Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.
The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.
Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101
Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression
1.
In Biochemically Recurrent Nonmetastatic Prostate Cancer, Apalutamide Presents Its Argument.
2.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Researchers find distinct cell receptors with the potential for new treatments.
5.
Taking vitamin D daily decreased cancer mortality, according to a study.
1.
Case Study: Diagnostic and Therapeutic Challenges in Aplastic Anemia Mimicking Hypoplastic Myelodysplastic Syndrome
2.
Unlocking the Mystery of Granulomas: A Closer Look at the Causes and Treatment
3.
The Mysterious Pain of Scrotal Hematoma: A Guide to Diagnosis and Treatment
4.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
5.
The Architect's Dilemma: Remodeling the Tumor Microenvironment for a New Era of Cancer Immunotherapy
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
3.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
5.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge